Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be released in late Q3
https://seekingalpha.com/news/4459791-skye-confirms-phase-2-data-nimacimab-obesity-expected-later-this-year
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.